文献速递术前评估与围术期医学

普通病房早期无创通气治疗急性呼吸衰竭的国际多中心随机试验

Early noninvasive ventilation in general wards for acute respiratory failure: an international, multicentre, open-label, randomised trial.
PubMed 文献 · Br J Anaesth · 2025-01-02

这项国际多中心开放标签随机对照试验纳入524例轻度急性呼吸衰竭(Pao2/FiO2≥200)成人患者,比较普通病房早期无创通气与常规治疗。早期无创通气组进展为严重急性呼吸衰竭的比例为18.5%,显著低于常规治疗组的28.3%(RR 0.65,95%CI 0.48-0.90,P=0.0080)。两组住院时长、呼吸并发症、28天死亡率及不良事件无差异。

要点

  • 普通病房轻度急性呼吸衰竭患者早期应用无创通气可降低进展为严重呼吸衰竭的风险。
  • 早期无创通气未缩短住院时长,也未改善28天死亡率或呼吸并发症。
  • 该策略在非ICU病房实施,不良事件与常规治疗无差异。

核心结论

  • 在非重症监护病房治疗的轻度急性呼吸衰竭患者中,早期无创通气可减少进展为严重急性呼吸衰竭。

研究设计与样本

  • 国际多中心、随机、开放标签对照试验,在意大利、希腊和哈萨克斯坦的11家医院纳入524例成人轻度急性呼吸衰竭患者(Pao2/FiO2≥200)。
  • 患者随机接受早期无创通气或常规治疗,早期无创通气组每8小时应用2小时无创通气周期,最长12天。

主要发现

  • 进展为严重急性呼吸衰竭在早期无创通气组为49/265(18.5%),常规治疗组为73/258(28.3%),相对风险0.65(95%CI 0.48-0.90,P=0.0080)。
  • 中位住院时长早期无创通气组为10天(IQR 6-16),常规治疗组为9天(IQR 5-16),P=0.30。
  • 呼吸并发症、28天死亡率和不良事件在两组间无差异。

临床怎么用

  • 对于普通病房收治的轻度急性呼吸衰竭成人患者,可考虑早期启动间歇性无创通气以预防病情恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of noninvasive ventilation (NIV) managed outside the intensive care unit in patients with early acute respiratory failure remains unclear. We aimed to determine whether adding early NIV prevents the progression to severe respiratory failure. METHODS: In this multinational, randomised, open-label controlled trial, adults with mild acute respiratory failure (arterial oxygen partial pressure/fraction of inspiratory oxygen [Pao2/FiO2] ratio ≥200) were enrolled across 11 hospitals in Italy, Greece, and Kazakhstan. Patients were randomised to receive early NIV or usual care. Patients in the early NIV group received 2-h cycles of NIV applied every 8 h for up to 12 days. The primary outcome was the progression to severe acute respiratory failure, defined by severe hypoxaemia, severe respiratory distress, or hypercapnic acidaemia during hospitalisation. RESULTS: Between May 6, 2012, and July 18, 2023, we randomised 524 patients (44.8% female; median age 73 yr, interquartile range [IQR] 63-83 yr). One patient withdrew consent. Progression to severe acute respiratory failure occurred in 49/265 (18.5%) patients randomised to early NIV, compared with 73/258 (28.3%) patients receiving usual care (relative risk 0.65, 95% confidence interval 0.48-0.90, P=0.0080). Median length of hospital stay was 10 (IQR 6-16) days in the early NIV group and 9 (IQR 5-16) days in the usual care group (P=0.30). Respiratory complications, 28-day mortality, and adverse events were not different between early NIV and usual care. CONCLUSIONS: In patients with mild acute respiratory failure treated in nonintensive care wards, early NIV reduced the progression to severe acute respiratory failure. CLINICAL TRIAL REGISTRATION: NCT01572337.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Monti G, Cabrini L, Kotani Y, et al. Early noninvasive ventilation in general wards for acute respiratory failure: an international, multicentre, open-label, randomised trial. Br J Anaesth. 2025. PMID: 39753402. doi:10.1016/j.bja.2024.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。